Literature DB >> 29780702

Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option.

Antonio Passaro1, Filippo de Marinis1.   

Abstract

Entities:  

Year:  2018        PMID： 29780702      PMCID： PMC5943218          DOI： 10.21037/tlcr.2018.02.09

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  14 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Authors:  Yi-Long Wu; Ying Cheng; Xiangdong Zhou; Ki Hyeong Lee; Kazuhiko Nakagawa; Seiji Niho; Fumito Tsuji; Rolf Linke; Rafael Rosell; Jesus Corral; Maria Rita Migliorino; Adam Pluzanski; Eric I Sbar; Tao Wang; Jane Liang White; Sashi Nadanaciva; Rickard Sandin; Tony S Mok
Journal:  Lancet Oncol       Date:  2017-09-25       Impact factor: 41.316

3.  First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

Authors:  Ji-Youn Han; Keunchil Park; Sang-We Kim; Dae Ho Lee; Hyae Young Kim; Heung Tae Kim; Myung Ju Ahn; Tak Yun; Jin Seok Ahn; Cheolwon Suh; Jung-Shin Lee; Sung Jin Yoon; Jong Hee Han; Jae Won Lee; Sook Jung Jo; Jin Soo Lee
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

4.  Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

Authors:  Keunchil Park; Eng-Huat Tan; Ken O'Byrne; Li Zhang; Michael Boyer; Tony Mok; Vera Hirsh; James Chih-Hsin Yang; Ki Hyeong Lee; Shun Lu; Yuankai Shi; Sang-We Kim; Janessa Laskin; Dong-Wan Kim; Catherine Dubos Arvis; Karl Kölbeck; Scott A Laurie; Chun-Ming Tsai; Mehdi Shahidi; Miyoung Kim; Dan Massey; Victoria Zazulina; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2016-04-12       Impact factor: 41.316

5.  Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

Authors:  Jessica J Lin; Stephanie Cardarella; Christine A Lydon; Suzanne E Dahlberg; David M Jackman; Pasi A Jänne; Bruce E Johnson
Journal:  J Thorac Oncol       Date:  2015-12-25       Impact factor: 15.609

6.  Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data.

Authors:  Antonio Passaro; Alessia Pochesci; Gianluca Spitaleri; Chiara Catania; Cristina Noberasco; Ester Del Signore; Filippo de Marinis
Journal:  Expert Rev Clin Pharmacol       Date:  2016-09-20       Impact factor: 5.045

7.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

8.  Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

Authors:  James Chih-Hsin Yang; Vera Hirsh; Martin Schuler; Nobuyuki Yamamoto; Kenneth J O'Byrne; Tony S K Mok; Victoria Zazulina; Mehdi Shahidi; Juliane Lungershausen; Dan Massey; Michael Palmer; Lecia V Sequist
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

9.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

Review 10.  Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?

Authors:  Nicolas Girard
Journal:  Future Oncol       Date:  2018-01-16       Impact factor: 3.404
View more
  2 in total

1.  Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study).

Authors:  Masahiro Iwasaku; Junji Uchino; Tadaaki Yamada; Yusuke Chihara; Takayuki Shimamoto; Nobuyo Tamiya; Yoshiko Kaneko; Fumiaki Kiyomi; Koichi Takayama
Journal:  Transl Lung Cancer Res       Date:  2019-08

Review 2.  A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors.

Authors:  Mohammed I El-Gamal; Nada H Mewafi; Nada E Abdelmotteleb; Minnatullah A Emara; Hamadeh Tarazi; Rawan M Sbenati; Moustafa M Madkour; Seyed-Omar Zaraei; Afnan I Shahin; Hanan S Anbar
Journal:  Molecules       Date:  2021-12-05       Impact factor: 4.411
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.